Skip to main content
. Author manuscript; available in PMC: 2015 Jul 27.
Published in final edited form as: J Cancer Ther. 2012 Oct;3(5A):689–711. doi: 10.4236/jct.2012.325089

Figure 2.

Figure 2

Molecular design and chemical composition of two covalent gemcitabine-immunochemotherapeutics. Legends: (Top-Panel) Gemcitabine-(C4-amide)-[anti-HER2/neu] synthesized using a 2-stage organic chemistry reaction scheme that initially creates a covalent bond at the C4 cytosine-like amine group of gemcitabine. (Bottom-Panel) Gemcitabine-(C5-methylcarbamate)-[anti-HER2/neu] synthesized using a 3-stage organic chemistry reaction scheme that formed covalent bonds at the chemotherapeutic C5-methylhydroxy group and at/to thiolated lysine α-amine groups residing within the amino acid sequence of anti-HER2/neu monoclonal immunoglobulin fractions.